LSE:GSK.L News 28 November 2025 - 7 February 2026

GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.

GSK shares fell 0.9% to 1,883.5 pence after late-stage hepatitis B trial results lacked detailed cure-rate data. The company reported European approval for new Shingrix packaging and Japanese approval for depemokimab. Investors await full bepirovirsen data and upcoming events, including the JPMorgan Healthcare Conference on Jan. 13.

GSK plc (LON:GSK; NYSE:GSK) is drifting quietly higher on Friday, 28 November 2025, with investors digesting a fresh “Hold” consensus from Wall Street, another round of share buybacks and a still‑busy drug pipeline that has pushed the stock close to 12‑month highs. In London, GSK’s shares are trading around 1,806p, up roughly 0.2% on the day, within a narrow intraday range of 1,802.5p–1,810p and not far from their 52‑week high of 1,830p.Investing.com+1 On the New York Stock Exchange, the company’s American Depositary Receipts (ADRs) change hands at about $48.02, virtually flat in early trading but hovering just below a 12‑month